In order to be enrolled in this study, subjects must meet the following inclusion criteria: (I) be aged 18–75 years old; (II) meet the diagnostic criteria of the “Guidelines for Primary Diagnosis and Treatment of ST-segment Elevation Myocardial Infarction (2019)” (11 (link)); (III) have received a coronary intervention within 12 hours.
Subjects were excluded from the study if they met any of the following exclusion criteria: (I) had severe heart valve disease, severe congenital heart disease, pulmonary heart disease, or hypertrophic obstructive cardiomyopathy; (II) had liver dysfunction [which was defined as alanine transaminase (ALT) or total bilirubin >3 times the upper normal limit], or renal insufficiency (which was defined as serum creatinine >1.5 times the normal upper limit); (III) were at high risk of bleeding; (IV) had an active peptic ulcer or skin ulcer; (V) were allergic to antiplatelet drugs; (VI) had cardiogenic shock; (VII) had a malignant tumor; (VIII) had a left main lesion as shown by CAG.
Subjects were excluded from the study if they met any of the following exclusion criteria: (I) had severe heart valve disease, severe congenital heart disease, pulmonary heart disease, or hypertrophic obstructive cardiomyopathy; (II) had liver dysfunction [which was defined as alanine transaminase (ALT) or total bilirubin >3 times the upper normal limit], or renal insufficiency (which was defined as serum creatinine >1.5 times the normal upper limit); (III) were at high risk of bleeding; (IV) had an active peptic ulcer or skin ulcer; (V) were allergic to antiplatelet drugs; (VI) had cardiogenic shock; (VII) had a malignant tumor; (VIII) had a left main lesion as shown by CAG.
